Estimating the Risks and Benefits of Nicotine Replacement Therapy for Smoking Cessation in the United States

12 de janeiro de 20103min

American Public Health Association
RESEARCH AND PRACTICE

Estimating the Risks and Benefits of Nicotine Replacement Therapy for Smoking Cessation in the United States

Benjamin J. Apelberg, PhD, MHS, Georgiana Onicescu, ScM, Erika Avila-Tang, PhD, MHS and Jonathan M. Samet, MD, MS

At the time of the study, Benjamin J. Apelberg, Georgiana Onicescu, Erika Avila-Tang, and Jonathan M. Samet were with the Institute for Global Tobacco Control, Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD.

Correspondence: Correspondence should be sent to Benjamin J. Apelberg, Institute for Global Tobacco Control, Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, 21205 (e-mail: bapelber@jhsph.edu). Reprints can be ordered at http://www.ajph.org by clicking on the “Reprints/Eprints” link.

 

Objectives. To compare potential population-wide benefits and risks, we examined the potential impact of increased nicotine replacement therapy (NRT) use for smoking cessation on future US mortality.

Methods. We developed a simulation model incorporating a Monte Carlo uncertainty analysis, with data from the 2005 National Health Interview Survey and Cancer Prevention Study II. We estimated the number of avoided premature deaths from smoking attributable to increased NRT use, before and after incorporating assumptions about NRT harm.

Results. We estimate that a gradual increase in the proportion of NRT-aided quit attempts to 100% by 2025 would lead to 40 000 (95% credible interval = 31 000, 50 000) premature deaths avoided over a 20-year period. Most avoided deaths would be attributable to lung cancer and cardiovascular disease. After we incorporated assumptions about potential risk from long-term NRT, the estimate of avoided premature deaths from all causes declined to 32 000.

Conclusions. Even after we assumed some harm from long-term NRT use, the benefits from increased cessation success far outweigh the risks. However, the projected reduction in premature mortality still reflects a small portion of the tobacco-related deaths expected over a 20-year period.

 


Sobre a UNIAD

A Unidade de Pesquisa em álcool e Drogas (UNIAD) foi fundada em 1994 pelo Prof. Dr. Ronaldo Laranjeira e John Dunn, recém-chegados da Inglaterra. A criação contou, na época, com o apoio do Departamento de Psiquiatria da UNIFESP. Inicialmente (1994-1996) funcionou dentro do Complexo Hospital São Paulo, com o objetivo de atender funcionários dependentes.



Newsletter


WP2Social Auto Publish Powered By : XYZScripts.com